Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI).
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3lrEq8M
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir
https://ift.tt/eA8V8J
No comments:
Post a Comment